Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 5/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | CALML3 | P27482 | 1/20 | 0.59 |
| ▸ | SDHA | P31040 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 7/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dup-721 SCHEMBL9521400 | 1.00 | ABCB11 (0.59) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL9550268 | 0.96 | ABCB11 (0.56) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL9550285 | 0.96 | ABCB11 (0.56) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL13298924 | 0.90 | MAOA (0.61) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL10753981 | 0.89 | F10 (0.57) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL16703808 | 0.88 | MAOA (0.60) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL9550292 | 0.88 | MAOA (0.60) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL15367964 | 0.88 | MAOA (0.60) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL9815521 | 0.88 | F10 (0.50) | ABCB11MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7710474 | 0.88 | ABCB11 (0.55) | ABCB11MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048106-A1 | IMMUNOTHERAPY TARGETING TUMOR TRANSPOSABLE ELEMENT DERIVEDNEOANTIGENIC PEPTIDES IN GLIOBLASTOMA | INST CURIE (FR) | 2026-02-19 | — | — | US | disclosed |
| US-20250302930-A1 | IMMUNOTHERAPY TARGETING TUMOR TRANSPOSABLE ELEMENT DERIVED NEOANTIGENIC PEPTIDES IN GLIOBLASTOMA | LNSTITUT GUSTAVE-ROUSSY (FR) | 2025-10-02 | — | — | US | disclosed |
| CN-115466253-B | Oxazolidinone compound containing dithiocarbamic acid ester structure and preparation method thereof | 沈阳药科大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117904087-A | Halohydrin dehalogenase mutant and application thereof in preparation of chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2024-04-19 | — | — | CN | disclosed |
| CN-115677679-A | Oxazolidinone compound containing biaryl hydrazone structure and preparation method and application thereof | 沈阳药科大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-115466253-A | Oxazolidinone compound containing dithiocarbamate structure and preparation method thereof | 沈阳药科大学 | 2022-12-13 | — | — | CN | disclosed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| WO-2010032901-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069449-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20100069449-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20100063117-A1 | Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
| US-20100063117-A1 | Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| WO-2008127025-A1 | A NOVEL HETEROCYCLE OR ALKOXYAMINOMETHYL OXAZOLIDINONE DERIVATIVE AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD (KR) | 2008-10-23 | — | — | WO | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | ABCB11 193/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20100063117-A1 | Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | VRK1, ALPI, VRK2 | ABCB11 179/4885MAOA 2024/4885MAOB 1898/4885 |
| US-20260048106-A1 | IMMUNOTHERAPY TARGETING TUMOR TRANSPOSABLE ELEMENT DERIVEDNEOANTIGENIC PEPTIDES IN GLIOBLASTOMA | MICA, TAP1, TNFSF10 | ABCB11 4359/4885MAOA 4637/4885MAOB 4620/4885 |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | ABCB11 193/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | ABCB11 278/4885MAOA 4398/4885MAOB 4248/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | ABCB11 425/4885MAOA 3819/4885MAOB 3591/4885 |
| US-20100069449-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | VRK1, ALPI, VRK2 | ABCB11 179/4885MAOA 2024/4885MAOB 1898/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | ABCB11 193/4885MAOA 2505/4885MAOB 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.